Enzymotec Ltd(NASDAQ:ENZY) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $11.73M. Analysts estimated a revenue of $14.90M. Earnings per share were $0.04. Analysts had estimated an EPS of $0.08.
Enzymotec Ltd (ENZY) made into the market gainers list on Wednesdays trading session with the shares advancing 0.14% or 0.01 points. Due to strong positive momentum, the stock ended at $7.26, which is also near the day’s high of $7.68. The stock began the session at $7.31 and the volume stood at 65,498 shares. The 52-week high of the shares is $10.7 and the 52 week low is $6.6. The company has a current market capitalization of $165 M and it has 2,27,18,335 shares in outstanding.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies research expertise and clinical validation process enable it to develop differentiated solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs medical disorders and common diseases. The Company’s technologies enable it to identify appropriate lipid-modifying enzymes and then improve the activity of these enzymes as well as to enable their use in organic media. These enzymes are then utilized to restructure lipids found in natural sources including krill fish vegetable sources and bovine milk. Its products include InFat Soy-PS PS and GPC Line of Products krill oil Vayarin Vayacog and Vayarol.